Prostate Cancer Research at City of Hope
July 1, 2024
This page was reviewed under our medical and editorial policy by Wesley Yip, M.D., assistant professor, Division of Urology and Urologic Oncology, Department of Surgery; Tanya Barauskas Dorff, M.D., professor, Department of Medical Oncology & Therapeutics Research; Jeffrey Y.C. Wong, M.D., professor, Department of Radiation Oncology; and Percy Lee, M.D., professor, Department of Radiation Oncology, City of Hope
At City of Hope, prostate cancer clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. Our patients have access to a wide variety of clinical trials, including innovative chemotherapy, targeted therapies and hormone therapies with fewer side effects, as well as advanced surgical techniques, radiation approaches and prevention strategies.
City of Hope's Prostate Cancer Research
City of Hope is a leader in prostate cancer research, with the following among the projects currently being investigated:
- Using focused ultrasound to heat up and destroy prostate cancer.
- Identifying and incorporating biomarkers for better detection of prostate cancer development, progression and recurrence, possibly bypassing the need for biopsies to make a diagnosis.
- Using neural stem cells to target and deliver cancer-fighting drugs to prostate cancer cells throughout the body.
- Identifying new imaging methods to detect microscopic disease outside the prostate.
- Using reengineered immune cells to target and attack prostate cancer throughout the body.
- Examining the benefits of surgery for patients with metastatic prostate cancer.
- Using natural therapies to help prevent prostate cancer recurrence.
- Following up with prostate cancer survivors to detect and manage long-term side effects and improve their quality of life.
What Are the Ongoing Clinical Trials for Prostate Cancer?
Compassionate patient care means a commitment to research. Not only do our clinical trials give current patients access to promising, leading-edge therapies — they also improve overall care for future patients worldwide.
For instance, City of Hope is conducting a clinical trial evaluating the role of neoadjuvant chemotherapy for patients with high-risk prostate cancer and BRCA1 or BRCA2 mutations.